Telomir Pharmaceuticals (TELO) vs Zhengye Biotechnology (ZYBT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Zhengye Biotechnology (ZYBT) has outperformed Telomir Pharmaceuticals (TELO) over the past year, losing 36.4% versus a loss of 42.0%. Telomir Pharmaceuticals is the larger company by market cap ($82.5 million vs $82.0 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | TELO | ZYBT |
|---|---|---|
| Share price | $1.12 | $1.73 |
| Market cap | $82.45M | $81.99M |
| 1-day change | -2.61% | +50.45% |
| YTD return | -15.79% | +50.43% |
| 1-year return | -41.97% | -36.40% |
| EPS (TTM) | $-1.11 | $-0.20 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $1.75 | $8.01 |
| 52-week low | $0.888 | $0.616 |
| Distance from 52-week high | -36.00% | -78.40% |
| Analyst consensus | none | — |
| Avg. price target upside | +257.14% | — |
| Average volume | 99.06K | 5.19M |
| Shares outstanding | 73.62M | 47.39M |
| Employees | — | 269 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Telomir Pharmaceuticals
TELO stock →Telomir Pharmaceuticals, Inc., a preclinical-stage biotechnology company, focuses on the development of small-molecule therapeutics designed to address upstream biological drivers of aging and age-related diseases. It is developing Telomir-1, an oral small molecule metal ion regulator designed to protect against age-related conditions, including Wilson's disease, Type 2 diabetes, age-related macular degeneration (AMD), oncology, and epigenetic regulation, as well as Alzheimer's disease and Progeria.
Health Care · Biotechnology: Pharmaceutical Preparations
About Zhengye Biotechnology
ZYBT stock →Zhengye Biotechnology Holding Limited engages in the research, development, manufacture, and sale of veterinary vaccines for livestock in the People's Republic of China. The company offers vaccines for swine, cattle, goats, sheep, poultry, and dogs, as well as monovalent vaccine, polyvalent vaccine, combined vaccine, and combined and polyvalent vaccine.
Health Care · Biotechnology: Pharmaceutical Preparations · 269 employees
TELO vs ZYBT FAQ
Which is bigger, Telomir Pharmaceuticals or Zhengye Biotechnology?
Telomir Pharmaceuticals (TELO) is larger, with a market capitalization of $82.45M compared with $81.99M for Zhengye Biotechnology (ZYBT).
Which stock has performed better over the past year, TELO or ZYBT?
ZYBT returned -36.40% over the past 12 months, compared with -41.97% for TELO (price return, excluding dividends). Past performance does not predict future results.
Are Telomir Pharmaceuticals and Zhengye Biotechnology in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.